Tegafur (2500 μmol, b.i.d.) | |||
Fa | 1 | Anttila et al., 1983 | |
k a | 0.1/min−1a | ||
K p | 1 (assumed) | ||
fb | 0.6 | fb = fu/RB, RB = 1 was assumed. | Benvenuto et al., 1978 |
CLint,1 | 24.8 ml/min3-a | CLint for non-5-FU pathway | |
CLint,2 | 5.2 ml/min3-a | CLint for 5-FU pathway | |
Vsys | 12,500 ml3-a | ||
5-FU | |||
K p | 1 (assumed) | ||
fb | 0.9 | fb = fu/RB, RB = 1 was assumed. | Goodman and Gilman, 1996 |
CLtot | 1070 ml/min | Heggie et al., 1987 | |
CLh | 856 ml/min | CLtot × 0.8 | Diasio and Harris, 1989 |
CLint | 2030 ml/min | according to well-stirred model | |
K m | 23 μM | Yamazaki et al., 1996 | |
V max | 46,700 nmol/min | calculated by CLint × K m | |
CLr | 214 ml/min | CLtot × 0.2 | Diasio and Harris, 1989 |
V sys | 13,100 ml | Heggie et al., 1987 | |
Physiological parameters | |||
Q | 1610 ml/min | ||
Vliver | 2800 ml | ||
Vpv | 70 ml | ||
E0 | 0.24 nmol/g liver | Present study (see Fig. 3) | |
k deg | 0.00024/min−1b | Yan et al., 1997 |
↵3-a Calculated by equations 13-16 to fit the reported blood concentration (Nakajima et al., 1980).
3-b Calculated from the recovery pattern of 5-FU-reducing activity of DPD in peripheral blood mononuclear cells after administration of sorivudine.